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Prognosis of gastric and esophageal cancer is poor and treatment improvements are
needed. Programmed cell death 1 receptor (PD-1) interaction with its ligand PD-L1
in tumor micro-environment promotes immune tolerance and blocking monoclonal
antibodies have entered clinical practice. However, clinical significance of PD-1 and
PD-L1 expression in gastric and esophageal adenocarcinomas, particularly in non-Asian
patients, is still unclear. Three tissue microarrays including 190 clinically annotated
esophageal (n = 31) and gastric (n = 159) adenocarcinomas and 58 paired mucosa
specimens, were stained with PD-1, PD-L1, and CD8-specific reagents in indirect
immunohistochemistry assays. PD-L1 expression was detectable in 23.2% of cancer
specimens. High PD-1 expression was detectable in 37.3% of cases and high
CD8+ infiltration in 76%. PD-L1 and high PD1 expression significantly correlated with
each other (rs = 0.404, P < 0.0001) and both significantly correlated with CD8+
infiltration (rs = 0.435, P = 0.0003, and rs = 0.444; P = 0.0004, respectively).
CD8+ lymphocyte infiltration correlated with improved survival in univariate (P = 0.009),
but not multivariate analysis. Most interestingly, multivariate analysis and Kaplan-Meier
curves indicate that combined low PD-1/PD-L1 expression and low CD8+ lymphocyte
infiltration significantly correlate with poor prognosis. Our data document the clinical
significance of a microenvironmental signature including PD-1/PD-L1 expression and
CD8+ lymphocyte infiltration in gastric and esophageal adenocarcinomas and contribute
to identify a patients’ subset requiring more aggressive peri-operative treatments.
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INTRODUCTION
Gastric and esophageal cancers are major causes of cancer-
related death. While esophageal cancer is the sixth most
common cause of cancer-related death worldwide, gastric cancer
is the second, with a high incidence in Asian countries
(1). Localized tumors are routinely treated with surgical
resection. However, even after potentially curative resection,
overall survival (OS) is poor (2, 3), and innovative therapeutic
approaches are needed.
Interaction of programmed death 1 (PD-1) immune
checkpoint protein with its ligands PD-L1 and PD-L2 inhibits
anticancer immune responses (4, 5). Therefore, monoclonal
antibodies (mAb) preventing it are currently utilized in cancer
treatment (6–11). The use of immune checkpoint inhibitors
has also been suggested for gastric and esophageal cancer
treatment and different clinical trials have shown promising
results (12–16), as recently reviewed (17). Notably, the anti-PD-1
antibody nivolumab (Opdivo R©) is approved in Japan as third-
line treatment for gastric cancer and the anti-PD-1 antibody
pembrolizumab (Keytruda R©) recently received FDA approval
for the treatment of patients with PD-L1 positive gastric and
gastroesophageal junction adenocarcinoma.
Responsiveness to immunotherapy critically depends on
the characteristics of tumor immune contexture (18, 19).
Therefore, it is important to investigate CD8+, PD-1+,
and PD-L1+ cell infiltration in large numbers of clinical
specimens. Yet, the few published studies addressing gastric
and esophageal cancer frequently yield conflicting results.
Importantly, due to the high incidence of these cancers, most
studies are from East Asia. However, gastric and esophageal
carcinomas in Asian and non-Asian patients are characterized
by different clinical course and immune infiltration (20).
Moreover, molecular subtypes may be characterized by different
microenvironment composition and expression of checkpoint
molecules (21, 22). Therefore, studies from different geographic
areas are necessary.
Due to limited number of reports fromWestern countries and
their low patient numbers, there is still a paucity of data regarding
prognostic relevance, and therapeutic potential of CD8+ and
PD-1+/PD-L1+ infiltration in gastric and esophageal cancers. In
this study, we addressed these issues by using tissue microarray
(TMA) technology.
Whole-genome sequence studies classify gastric
adenocarcinoma (GAC) into four different subtypes: (i)
Epstein-Barr virus (EBV) positive tumors, characterized by
PD-L1/-L2 amplification, (ii) microsatellite unstable (MSI)
cancers, (iii) tumors with chromosomal instability, and (iiii)
genomically stable tumors (22). In esophageal cancers, three
molecular subclasses of squamous cell carcinomas (ESCC) were
identified, whereas adenocarcinomas (EAC) closely resemble
chromosomal unstable gastric cancers (21). Most recently, EBV+
and MSI gastric cancers have been shown to respond to anti
PD-1 treatment (23).
Since our earlier studies (Däster et al., unpublished data)
indicate that ESCC are poorly infiltrated by immune cells,
and considering their highly specific molecular features,
in this study we focused on the analysis of gastric and
esophageal adenocarcinomas.
MATERIALS AND METHODS
Tissue Microarray Construction
Three TMA blocks of non-consecutive primary esophageal
and gastric cancer and paired non-malignant adjacent tissue
specimens were constructed by using TMA-Grand Master R©
(3DHisteck, Sysmex AG, Switzerland). TMAs contained 1mm
cores of 190 gastric and esophageal adenocarcinomas together
with 58 non-malignant mucosa samples. All specimens were
part of the Biobank at the Institute of Pathology, University
Hospital Basel, Switzerland. For TMA construction, formalin-
fixed, paraffin-embedded tissue blocks were prepared according
to standard protocols. All cancer cores were checked for their
percentage of tumor cells and this value was above 50% for all
cancer samples.
Data Collection
Clinical and histopathology data were collected retrospectively
in a non-stratified and non-matched manner. Data included
patients’ age, primary cancer site, TNM stage, disease-specific
survival, histological subtype, presence of vascular invasion, and
tumor diameter and grade. Approval for the use of samples
and data was obtained from local ethics committee (Permission
361/12 EKBB).
Immunohistochemistry
All analyses have been performed on Ventana BenchMark Ultra.
Primary antibodies used were specific for CD8 (Ventana 790-
4460 clone sp57, Roche, Switzerland), PD-1 (Ventana 760-4895,
Roche, Switzerland), and PD-L1 (Ventana SP263 assay, Roche,
Switzerland). According to manufacturer’s OptiView procedures,
the following pre-incubation and first mAb times were utilized:
24 and 16min, 48 and 12min, 56 and 12min for anti-CD8, -
PD1, and -PD-L1, respectively. Immunohistochemistry (IHC)
evaluation was performed by a senior consultant pathologist
[LTO]. Intraepithelial and stromal CD8+ cells were counted
for each TMA punch (approximately one high power [20x]
field). For PD-1 and PD-L1 staining, percentages of positive
cells/total number of cells, and staining intensities (0 = negative,
1 = weak, 2 = moderate, 3 = strong) were considered
for each TMA punch. PD-1-positivity was only detectable in
tumor infiltrating lymphocytes, whereas PD-L1-positive cells
included tumor and immune cells, which were evaluated
in combination. Subsequently, PD-1 and PD-L1 histoscores
were obtained by multiplying percentages of positive cells by
staining intensity.
Statistical Analysis
Data were analyzed using the Statistical Package Software
R (Version 3.4.1, www.r-project.org). Descriptive statistics
included mean ± standard deviation for parameters with
Gaussian distribution or percentage of frequencies for
occurrences for discrete variables. Cut-off values used to
classify tumors with low or high infiltration of positive
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cells/histoscores were calculated by regression tree analysis
(rpart package). Thereafter, based on the results (high/low)
of all three markers, tumors were classified into three
groups “PD-1/PD-L1/CD8 high” (high PD-1 and PD-L1
histoscores, high infiltration of CD8+ cells), “PD-1/PD-
L1/CD8 low” (low PD-1 and PD-L1 histoscores, low
infiltration of CD8+ cells), and “PD-1/PD-L1/CD8 mixed”
(the remaining tumors).
Chi-square, Fisher’s exact, Mann-Whitney-Wilcoxon,
Kruskal-Wallis, and Jonckheere-Terpstra tests were used
to determine the association of CD8, PD-1, and PD-L1
positivity and clinical-pathological features. Relationships
between continuous markers were calculated using
Spearman’s correlation.
Survival analysis was carried out by Cox regression analysis
and Kaplan-Meier curves were compared by log rank test. Any
missing clinical-pathological information was assumed to be
missing at random. Multivariate Cox regression analysis and
hazard ratios (HR) and 95% confidence intervals (CI) were
used to determine prognostic effects on survival. P ≤ 0.05 were
considered statistically significant.
RESULTS
Patient and Tumor Characteristics
Clinical pathological characteristics of patients under
investigation (n = 190) are reported in Table 1. Tissue samples
from 31 esophageal adenocarcinoma to 10 paired non-malignant
esophageal biopsies, as well as 159 gastric cancers and 48
non-malignant paired gastric tissue biopsies were evaluated.
Four EAC were gastroesophageal junction tumors. Over 75% of
tumors were in T2-3 stage and over 70% were in N0-1 stage. A
majority of tumors were characterized by a G3 histological grade.
Median overall survival (OS) time in the whole cohort was 8
months (range 0–191) and 5-year OS rate was 51.0% (95% CI
= 41.6–62.5).
CD8, PD-1, and PD-L1 Expression in
Gastric and Esophageal Adenocarcinoma
Specimens
Representative examples of CD8, PD-1, and PD-L1-specific
staining are shown in Figure 1. Total number of CD8+
lymphocytes detectable within tumor and stroma ranged between
0 and 548 (mean = 95 ± 9.6, median = 66). Tissue specimens
were dichotomized as highly (76.2%) or poorly (23.8%)
infiltrated, based on a threshold value of 33 CD8+ cells per 1mm
diameter punch, as identified by regression tree analysis. This
value also corresponds to the first quartile of infiltrating CD8+
lymphocytes counted in this cohort. The calculated histoscore for
PD-1+ (percentage of positive cells multiplied by intensity) in
gastric and esophageal adenocarcinoma samples ranged between
0 and 210 (mean = 23 ± 39, median = 4) and a threshold value
of 14 was calculated. PD-L1 histoscore, considering all positive
cells in each punch, ranged between 0 and 160 (mean= 6.8± 21,
median and third quartile = 0). Therefore, samples were scored
as positive when at least one cell was specifically stained. Thus, a
TABLE 1 | Clinical-pathological characteristics of the overall gastric and
esophageal adenocarcinoma patient cohort (n = 190).
Characteristics
Patients’ age mean/median (range) 69/71 (27–90)
Tumor size in mm mean/median (range) 54/45 (10–180)
Localization
Esophagus 27 (14.2%)
Esophago-gastric junction 4 (2.1%)
Stomach 159 (83.7%)
Sex
Female 58 (30.5%)
Male 132 (69.5%)
T stage
T1 26 (13.7%)
T2 68 (37.9%)
T3 72 (37.9%)
T4 24 (12.6%)
N stage*
N0 61 (32.1%)
N1 78 (41.1%)
N2 27 (14.2%)
N3 22 (11.6%)
Tumor grade**
G1 7 (3.7%)
G2 52 (26.4%)
G3 115 (63.4%)
Vascular invasion
No (%) 26 (13.7%)
Yes (%) 78 (41.5%)
unknown 86 (44.8%)
*Data not available for 2 patients.
** Data not available for 16 patients.
positive signal was detectable in 43/185 tumors (23.2%), but in no
normal tissue.
Notably, a moderately positive correlation was observed
between PD-1+ and PD-L1 histoscores (rs = 0.404; P < 0.0001)
and between each of these scores and CD8+ cell infiltration (rs =
0.444; P < 0.0004 and rs = 0.435; P = 0.0003, respectively).
While there was no significant difference in CD8+ infiltration
between cancers and normal mucosa samples (P = 0.480), a
significantly higher number of cancer samples was characterized
by higher PD-1 histoscore, as compared to paired normal tissues
(P < 0.0001) (Supplementary Figure 1).
Univariate and Multivariate Analysis of
CD8, PD-1, and PD-L1 Expression in
Gastric and Esophageal Adenocarcinomas
We initially analyzed the prognostic significance of the
expression of individual markers. Univariate Cox regression
analysis indicated that CD8+ infiltration was highly significantly
(p = 0.009) associated with improved 5 years OS (Table 2).
Instead, higher PD-1 and PD-L1 scores were barely significantly
associated “per se” with OS (P = 0.056 and P = 0.05,
respectively). Notably however, a tumor microenvironment
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FIGURE 1 | CD8-, PD-1-, PD-L1 specific staining in gastric and esophageal
adenocarcinoma TMA. Representative CD8, PD-1, and PD-L1-specific
staining in TMA punches. Specimens were stained with CD8- (B), PD-1- (D),
and PD-L1- (F) specific reagents. (A, C, E) refer to punches stained with
isotype control reagents. Scale bar: 500µm.
“signature” including high CD8+ cell infiltration and high
PD1/PD-L1 scores was associated with significantly higher OS
(P = 0.005). As expectable, pN stage (pos. vs. neg.) appeared to
significantly impact on OS (P = 0.01).
Upon multivariate analysis, as expectable, pN stage (pos. vs.
neg.) emerged as critical variable significantly associated with
poor OS (HR:3.82; 95%CI:1.51–11.09; P = 0.008) (Table 2).
Most interestingly however, low CD8+ lymphocyte infiltration
coupled with low PD-1/PD-L1 scores (PD-1/PD-L1/CD8
low) also significantly correlated with poor OS in gastric
and esophageal adenocarcinomas (HR;0.53; 95%CI:0.29–
0.96; P = 0.037). Separate analysis of gastric and esophageal
adenocarcinomas is reported in Supplementary Tables 1A,B.
Impact of PD-1/PD-L1/CD8 Signature in
Gastric and Esophageal Adenocarcinomas
Subsequently, we explored clinical-pathological features in
the three subgroups identified by uniformly high or low
TABLE 2 | Uni- and multivariate Hazard Cox regression survival analysis in the
whole cohort of gastric and esophageal cancers.
Univariate Multivariate
HR 95% CI p-
values
HR 95% CI p-
values
CD8* 0.41 0.21–0.80 0.009
PD-1 histoscore* 0.47 0.21–1.02 0.056
PD-L1 histoscore* 0.39 0.15–1.00 0.050
PD1 PDL1 CD8
Score**
0.44 0.25–0.78 0.005 0.53 0.29–0.96 0.037
Age 0.99 0.97–1.02 0.798 1.01 0.98–1.04 0.623
Gender
(men vs. women)
1.36 0.67–2.75 0.392 1.27 0.51–3.21 0.601
pT stage
(T3-4 vs. T1-2)
1.72 0.94–3.15 0.076 1.66 0.82 – 3.40 0.160
Tumor grade
(high vs. low)
1.17 0.63–2.16 0.623 0.84 0.39–1.82 0.647
pN stage
(pos. vs. neg.)
2.49 1.24–5.01 0.010 3.82 1.51–11.09 0.008
Uni- and multivariate Cox-regression analyses showing Hazard Ratios and P-values
(Wald test).
*Not included in the multivariate model.
**All three markers low, mixed or all high.
CD8+ infiltration and PD1/PD-L1 scores (PD-1/PD-L1/CD8
high and PD-1/PD-L1/CD8 low) or mixed results (PD-1/PD-
L1/CD8 high and/or low). Complete follow-up data were
available for 161 patients, including 133 gastric, and 28
esophageal adenocarcinomas. PD-1/PD-L1/CD8 high signature
was detectable in slightly older patients as compared with the
mixed or low signature (p = 0.046), but was independent
from patients’ gender, tumor size, tumor grade, and pN (data
not shown).
Most importantly, survival analysis indicates that gastric
and esophageal adenocarcinomas with PD-1/PD-L1/CD8 “low”
signature is characterized by poor long-term prognosis, as
compared with the other two subgroups under investigation
(p = 0.015, Figure 2). In particular, PD-1/PD-L1/CD8 “low”
signature is characterized by poor long-term prognosis, as
compared to the “high” (p = 0.008) or mixed signature
group (p = 0.03), in spite of an apparent initial overlap of
the survival curve of the latter. In contrast, due to relatively
low numbers of patients under investigation, difference
in survival curves of patients with “high” or “mixed”
signature failed to reach statistical significance threshold
(p = 0.2). A separate analysis of Kaplan-Meier curves
for gastric and esophageal adenocarcinomas is reported in
Supplementary Figures 2A,B.
DISCUSSION
PD-1/PD-L1 axis plays a crucial role in inhibiting T lymphocyte
functions, allowing cancer cells to escape adaptive immune
response (4, 5). It has been suggested that “inflamed” tumors with
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FIGURE 2 | Prognostic significance of PD-1/PD-L1/CD8 signature in gastric
and esophageal adenocarcinoma. Kaplan-Meier curves depict the impact of
the consistently high (green line), low (black line), or mixed (red line) expression
of the indicated markers in tumor microenvironment on the overall survival of
patients with gastric and esophageal adenocarcinomas. Long-term follow-up
data were available for 161 patients. P = 0.015.
high CD8+ T cell infiltration and high PD-1/PD-L1 expression
might most benefit from PD-1/PD-L1 blockade (18).
Due to higher epidemiological relevance, gastric, and
esophageal cancers have mainly been studied in Asian
cohorts, and there are only few reports focusing on tumor
microenvironment in non-Asian patients. However, particularly
regarding gastric cancers, distinct gene expression profiles
were detected in tumors from Asian and Western cohorts with
significantly higher expression of T cell markers in the Western
population (20).
In studies focusing on East Asian patients, PD-L1 was shown
to be expressed in up to 40% of tumor cells in esophageal cancers,
but its prognostic significance is debated (24–27). In a cohort of
Western patients, PD-L1 expressionwas reported to be associated
with a favorable clinical course (28).
In gastric cancers, most studies from Asian patients
demonstrated immunohistochemical PD-L1 expression in
around 40% of tumors and an association with poor survival
(29–33), as supported by a recent meta-analysis (34). However,
association with favorable prognosis has also been reported (35).
In a Western population of 465 gastric cancer patients, PD-L1
expression was detected in 30% of tumor cells and was associated
with better outcome (36). However, association with adverse
prognosis was also reported by others (37).
Prognostic significance of PD-1 expression in esophageal and
gastric cancers is also debated (27, 29, 30, 35–37).
Regarding CD8+ T cells, current understanding is that
high infiltration correlates with improved outcome, as shown
in both esophageal (38, 39) and gastric cancers (20, 40–42)
in both Asian and non-Asian patients. However, conflicting
data have also been published and a recent report in gastric
cancer has surprisingly suggested an association between high
CD8+ T cell density and poor survival (37). Importantly, CD8
expression was also associated with PD-L1 expression in that
cohort (37).
Interestingly, contrasting data have been reported regarding
the extent of CD8+ lymphocyte infiltration in these cancers,
as compared to corresponding healthy tissues, possibly
reflecting differences related to different tumor subtypes
(38, 43–46) and Helicobacter pylori status. In our study,
we did not observe significant differences in cancer, as
compared to healthy tissue CD8+ T cell infiltration. However,
consistent with previous reports (44–46), in our series PD-
1 expression was increased in cancerous, as compared to
normal tissues, whereas PD-L1 expression was undetectable in
healthy tissues.
Our data document that although CD8+ T cell infiltration,
and, to lower extents, PD-1/PD-L1 expression appear to be
associated with improved 5 years OS in univariate analysis, none
of these markers significantly correlates “per se” with survival
in multivariate analysis. Most interestingly however, a combined
immunohistochemical analysis reveals that low PD-1/PD-
L1/CD8 expression in gastric and esophageal adenocarcinoma
microenvironment is associated with poor prognosis. Therefore,
patients bearing these tumors should be eligible for early and
more aggressive peri-operative treatments.
Our study has limitations. First, TMA technology does not
mirror tumor tissue heterogeneity. However, TMA punches
included at least 50% tumor cells and were taken from
the center of tumor specimens. Moreover, the numbers of
individual gastric and esophageal adenocarcinoma specimens
compensate, at least in part, for the heterogeneity of different
tumor areas. Secondly, the number of patients suffering
from esophageal adenocarcinoma is limited. Subsequently
the message of this study is consistent mainly for gastric
cancers. Lastly, the retrospective design of the study limits its
significance. Nevertheless, these data might help developing
further prospective andmechanistic studies and contribute to the
identification of subgroups of high-risk patients.
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